Selective estrogen receptor modulators and their effects on hot flashes: A dilemma

Menopause

Volumn 18, Issue 5, 2011, Pages 477-479

  Bouchard, Céline ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BAZEDOXIFENE; ESTROGEN; ESTROGEN RECEPTOR; NALOXONE; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

BREAST CANCER; CLIMACTERIUM; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HOT FLUSH; HUMAN; HYPOTHALAMUS; INCIDENCE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE OSTEOPOROSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); THERMOREGULATION; VASOMOTOR DISORDER;

EID: 85027926708     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e3182176285     Document Type: Editorial

References (17)

1. Shanafelt TD, Barton DL, Adjaei AA, Loprinzi CL. Pathophysiology and treatment of hot flashes. Mayo Clin Proc 2002;77:1207-1218. (Pubitemid 35266369)
2. Freeman EW, Sammel MD, Lin H, et al. Symptoms in the menopausal transition: hormone and behavioural correlates. Obstet Gynecol 2008;111:127-136.
3. Love RR, Cameron L, Connell BL, Leventhal H. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 1991;151:1842-1847.
4. Loprinzi CL, Zahaski KM, Sloan JA, Novotny PJ, Quella SK. Tamoxifen induced hot flashes. Clin Breast Cancer 2000;1:52-56.
5. Graham CD, Huster W, Lu Y, Plouffe L, Lakshmanan M. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol 1999;93:558-565. (Pubitemid 29147076)
6. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investgators. JAMA 1999;282:637-645. (Pubitemid 29384151)
7. Aldrighi JM, Quail DC, Levy-Febault J, et al. Predictors of hot flushes in postmenopausal women who receive raloxifene therapy. Am J Obstet Gynecol 2004;191:1979-1988. (Pubitemid 39601502)
8. Palacios S, Farias MLF, Luebbert H, et al. Raloxifene is not associated with biologically relevant change in hot flushes in postmenopausal women fro whom therapy is appropiate. Am J Obstet Gynecol 2004;191:121-131. (Pubitemid 39077964)
9. Mitwally MFM. Bazedoxifene: a selective estrogen-receptor modulator. Womens Health (Lond Engl) 2008;4:319-326.
10. Komm BS, Kharode YP, Bodine PV, Harris HA, Miller CP, Lyttle CR. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 2005;46:3999-4008. (Pubitemid 41175771)
11. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008;23:1923-1934.
12. Miller PD, Chines AA, Christiansen C, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized double-blind, placebo-, and active-controlled study. J Bone Miner Res 2008;23:525-535. (Pubitemid 351501893)
13. Bachmann G, Crosby U, Feldman RA, Ronkin S, Constantine GD. Effects of bazedoxifene on nonflushing postmenopausal women: a randomized phase 2 trial. Menopause 2011;18:508-514.
14. Stovall DW, Utian WH, Gass MLS, et al. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety. Menopause 2007;14:510-517.
15. Valiati B, Capp E, Edelweiss MI, Monteiro de Freitas F, Wender MCO. Effect of raloxifene and low-dose percutaneous 17A-estradiol on menopause symptoms and endometrium-a randomized controlled trial. Maturitas 2009;62:81-84.
16. Lobo R, Pinkerton JV, Gass MIS, et al. Evaluation of bazedoxifene/ conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 2009;92:1025-1038.
17. Archer DF. Tissue-selective estrogen complexes a promising option for the comprehensive management of menopausal symptoms. Drugs Aging 2010;27:533-544.